QUÉBEC CITY, May 31, 2012 /PRNewswire/ - Aeterna Zentaris Inc.

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules.

AEZS-136 shows synergy and efficacy in human tumor cells QUÉBEC CITY, April 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc.

Scientists at the Gladstone Institutes have discovered a key protein that regulates insulin resistance—the diminished ability of cells to respond to the action of insulin and which sets the stage for the development of the most common form of diabetes.

NEW YORK, Feb 21, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc.